Other
Asep Medical's Hancock resigns as CEO, chairman
ASEP · Price
Executive Summary
- Dr. Robert Hancock steps down as Chief Executive Officer and Chairman of the Board of Asep Medical Holdings Inc. to focus on scientific leadership at Sepset Biosciences Inc. and ABT Innovations Inc.
- The board has begun a search for a new CEO and chairman with strong bioscience and capital‑markets expertise.
- Dr. Hancock’s departure is acknowledged with gratitude; the company reaffirms its commitment to advancing sepsis diagnostics and anti‑biofilm technologies.
Key Details
- Departure: Dr. Robert Hancock resigns from both CEO and Chairman roles effective immediately.
- Reason: To intensify his role as CEO of Sepset Biosciences Inc. and ABT Innovations Inc., focusing on product commercialization, R&D, IP, and scientific strategy.
- Tenure: Served as Asep’s CEO and Chairman since July 5 2022 (following former CEO Rudy Mazzocchi’s health‑related departure).
- Board Statement: Board spokesperson Dr. Richard Heinzl praised Hancock’s vision and scientific expertise in advancing Asep’s mission.
- Search Initiated: The board is seeking a new CEO/Chairman with deep biosciences background, strong North American capital‑markets connections, and established global relationships to support strategic and financing objectives.
- Future Focus: Asep remains committed to delivering innovative diagnostic and therapeutic solutions for sepsis and antibiotic resistance.
Notable Quotes
- “Dr. Hancock's vision and scientific expertise have been instrumental in advancing Asep's mission,” – Dr. Richard Heinzl, Board Spokesperson.
- “We think this is a great opportunity to sharpen our focus — leveraging Dr. Hancock's world‑class scientific leadership while we seek a CEO with deep biosciences expertise and strong North American capital markets connections,” – Derrold Norgaard, Board Member.